Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease.

Howlett DR, Bowler K, Soden PE, Riddell D, Davis JB, Richardson JC, Burbidge SA, Gonzalez MI, Irving EA, Lawman A, Miglio G, Dawson EL, Howlett ER, Hussain I.

Histol Histopathol. 2008 Jan;23(1):67-76.

PMID:
17952859
2.

[The lesions of Alzheimer's disease: which therapeutic perspectives?].

Duyckaerts C, Perruchini C, Lebouvier T, Potier MC.

Bull Acad Natl Med. 2008 Feb;192(2):303-18; discussion 318-21. Review. French.

PMID:
18819685
3.

Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice.

Dewachter I, van Dorpe J, Spittaels K, Tesseur I, Van Den Haute C, Moechars D, Van Leuven F.

Exp Gerontol. 2000 Sep;35(6-7):831-41. Review.

PMID:
11053674
4.

Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.

Götz J, Schild A, Hoerndli F, Pennanen L.

Int J Dev Neurosci. 2004 Nov;22(7):453-65. Review.

PMID:
15465275
5.

Progress toward valid transgenic mouse models for Alzheimer's disease.

Guénette SY, Tanzi RE.

Neurobiol Aging. 1999 Mar-Apr;20(2):201-11. Review.

PMID:
10537029
6.

The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP?

Howlett DR, Richardson JC.

Histol Histopathol. 2009 Jan;24(1):83-100. Review.

PMID:
19012248
7.

Transgenic mouse models of Alzheimer's disease.

Bornemann KD, Staufenbiel M.

Ann N Y Acad Sci. 2000 Jun;908:260-6. Review.

PMID:
10911965
8.

APP transgenic mice and their application to drug discovery.

Howlett DR.

Histol Histopathol. 2011 Dec;26(12):1611-32. Review.

PMID:
21972099
9.
10.

Genetically modified mice models for Alzheimer's disease.

Sankaranarayanan S.

Curr Top Med Chem. 2006;6(6):609-27. Review.

PMID:
16712495
11.

Alzheimer's disease and amyloid: culprit or coincidence?

Skaper SD.

Int Rev Neurobiol. 2012;102:277-316. doi: 10.1016/B978-0-12-386986-9.00011-9. Review.

PMID:
22748834
12.

[Advances in molecular biology and clinical study of amyloid precursor protein for Alzheimer's disease].

Xu BG, Wu X.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004 Apr;26(2):201-9. Review. Chinese.

PMID:
15171563
13.

Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model.

Sturchler-Pierrat C, Staufenbiel M.

Ann N Y Acad Sci. 2000;920:134-9. Review.

PMID:
11193142
14.

Vaccines for Alzheimer's disease: how close are we?

Janus C.

CNS Drugs. 2003;17(7):457-74. Review.

PMID:
12751917
15.

Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease.

Suh YH, Checler F.

Pharmacol Rev. 2002 Sep;54(3):469-525. Review. Erratum in: Pharmacol Rev. 2006 Jun;58(2):280.

16.

A decade of modeling Alzheimer's disease in transgenic mice.

McGowan E, Eriksen J, Hutton M.

Trends Genet. 2006 May;22(5):281-9. Review.

PMID:
16567017
17.

APP transgenic mouse models and their use in drug discovery to evaluate amyloid- lowering therapeutics.

Hussain I.

CNS Neurol Disord Drug Targets. 2010 Aug;9(4):395-402. Review.

PMID:
20522015
18.

Mouse models of Alzheimer's disease: insight into treatment.

German DC, Eisch AJ.

Rev Neurosci. 2004;15(5):353-69. Review.

PMID:
15575491
19.

Alzheimer's disease: beta-Amyloid protein and tau.

Morishima-Kawashima M, Ihara Y.

J Neurosci Res. 2002 Nov 1;70(3):392-401. Review.

PMID:
12391602
20.

Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions.

Higuchi M, Iwata N, Saido TC.

Biochim Biophys Acta. 2005 Aug 1;1751(1):60-7. Review.

PMID:
16054018
Items per page

Supplemental Content

Support Center